KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares Repurchased
Ratios

Halozyme Therapeutics (HALO) Long-Term Debt Issuances (2016 - 2022)

Halozyme Therapeutics (HALO) has disclosed Long-Term Debt Issuances for 3 consecutive years, with $582.0 million as the latest value for Q4 2022.

  • Quarterly Long-Term Debt Issuances changed N/A to $582.0 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $702.0 million through Dec 2023, changed 0.0% year-over-year, with the annual reading at $735.0 million for FY2025, N/A changed from the prior year.
  • Long-Term Debt Issuances for Q4 2022 was $582.0 million at Halozyme Therapeutics, up from $120.0 million in the prior quarter.
  • The five-year high for Long-Term Debt Issuances was $784.9 million in Q1 2021, with the low at -$784.9 million in Q3 2021.